Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches

Transplantation

Volumn 100, Issue 10, 2016, Pages 2024-2038

  Anglicheau, Dany ^a,b,c   Naesens, Maarten ^d   Essig, Marie ^e,f   Gwinner, Wilfried ^g   Marquet, Pierre ^f  

^a INSTITUT NECKER ENFANTS MALADES   (France)

^b Paris Diderot Sorbonne Cite University   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF LIMOGES   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; ANTIBODY; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD163 ANTIGEN; CD72 ANTIGEN; CXCL9 CHEMOKINE; CYSTATIN C; DONOR SPECIFIC ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; BK VIRUS INFECTION; BK VIRUS INFECTION NEPHROPATHY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT RECIPIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIMIT OF QUANTITATION; PATHOPHYSIOLOGY; PATIENT CARE; PEPTIDOMICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TRANSCRIPTOMICS; ALLOGRAFT; DONOR; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY;

ALLOGRAFTS; BIOMARKERS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PROTEINURIA; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY;

EID: 84980409673     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001321     Document Type: Review

References (138)

1. Matas AJ, Gaston RS.Moving beyondminimization trials in kidney transplantation. J Am Soc Nephrol. 2015;26:2898-2901.
2. Henderson LK, Nankivell BJ, Chapman JR. Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice. Am J Transplant. 2011;11:1570-1575.
3. Naesens M. Zero-Time Renal Transplant Biopsies: A Comprehensive Review. Transplantation. 2016;100:1425-1439.
4. Halloran PF, Famulski K, Reeve J. The molecular phenotypes of rejection in kidney transplant biopsies. Curr Opin Organ Transplant. 2015;20:359-367.
5. Halloran PF, Reeve JP, Pereira AB, et al. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int. 2014;85:258-264.
6. Adam B, Mengel M. Transplant biopsy beyond light microscopy. BMC Nephrol. 2015;16:132.
7. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62:311-318.
8. Rabant M, Amrouche L, Lebreton X, et al. Urinary C-X-C motif chemokine 10 independently improves the noninvasive diagnosis of antibodymediated kidney allograft rejection. J Am Soc Nephrol. 2015;26: 2840-2851.
9. Lo DJ, Kaplan B, Kirk AD. Biomarkers for kidney transplant rejection. Nat Rev Nephrol. 2014;10:215-225.
10. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant. 2010;10:563-570.
11. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-1167.
12. Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant. 2007;7:356-365.
13. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378:1428-1437.
14. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;(9 Suppl 3):S1-S155.
15. Legendre C, Anglicheau D. Transplantation: proteinuria in kidney transplantation: an ongoing story. Nat Rev Nephrol. 2013;9:251-252.
16. Tsampalieros A, Knoll GA. Evaluation and management of proteinuria after kidney transplantation. Transplantation. 2015;99:2049-2060.
17. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant. 2007;7:2748-2756.
18. Cherukuri A, Welberry-Smith MP, Tattersall JE, et al. The clinical significance of early proteinuria after renal transplantation. Transplantation. 2010;89:200-207.
19. Halimi JM, Buchler M, Al-Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant. 2007;7:618-625.
20. Amer H, Lieske JC, Rule AD, et al. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant. 2013;13:676-684.
21. Naesens M, Lerut E, Emonds MP, et al. Proteinuria as a noninvasive marker for renal allograft histology and failure: an observational cohort study. J Am Soc Nephrol. 2016;27:281-292.
22. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21:1398-1406.
23. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: comparison of MFI, C1q, and titer information. Am J Transplant. 2015;15:2421-2430.
24. Naesens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol. 2010;6:614-628.
25. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation. 2008;86:192-199.
26. Perkins D, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol. 2011;33:211-218.
27. Traitanon O, Poggio ED, Fairchild RL. Molecular monitoring of alloimmune-mediated injury in kidney transplant patients. Curr Opin Nephrol Hypertens. 2014;23:625-630.
28. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant. 2005;5: 1971-1975.
29. Bestard O, Cruzado JM, Lucia M, et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int. 2013;84:1226-1236.
30. Mehrotra A, Leventhal J, Purroy C, et al. Monitoring T cell alloreactivity. Transplant Rev (Orlando). 2015;29:53-59.
31. Nickel P, Bestard O, Volk HD, et al. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant. 2009;14: 426-431.
32. Hricik DE, Augustine J, Nickerson P, et al. Interferon gamma ELISPOT testing as a risk-stratifying biomarker for kidney transplant injury: results from the CTOT-01 multicenter study. Am J Transplant. 2015;15: 3166-3173.
33. Ling X, Xiong J, Liang W, et al. Can immune cell function assay identify patients at risk of infection or rejection A meta-analysis. Transplantation. 2012;93:737-743.
34. Hope CM, Troelnikov A, Hanf W, et al. Peripheral natural killer cell and allo-stimulated T-cell function in kidney transplant recipients associate with cancer risk and immunosuppression-related complications. Kidney Int. 2015;88:1374-1382.
35. Aquino-Dias EC, Joelsons G, da Silva DM, et al. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int. 2008;73:877-884.
36. GuntherOP, Balshaw RF, Scherer A, et al. Functional genomic analysis of peripheral blood during early acute renal allograft rejection. Transplantation. 2009;88:942-951.
37. Kurian SM, Heilman R, Mondala TS, et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One. 2009;4:e6212.
38. Li L, Ying L, Naesens M, et al. Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples. Physiol Genomics. 2008;32:190-197.
39. Matz M, Fabritius K, Lorkowski C, et al. Identification of T cell-mediated vascular rejection after kidney transplantation by the combined measurement of 5 specific MicroRNAs in blood. Transplantation. 2016;100: 898-907.
40. Rascio F, Pontrelli P, Accetturo M, et al. A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation. J Pathol. 2015;237:72-84.
41. Simon T, Opelz G, Wiesel M, et al. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant. 2003;3:1121-1127.
42. Kurian SM, Williams AN, Gelbart T, et al. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. Am J Transplant. 2014;14:1164-1172.
43. Roedder S, Sigdel T, Salomonis N, et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med. 2014;11:e1001759.
44. Li L, Khatri P, Sigdel TK, et al. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant. 2012;12: 2710-2718.
45. Braud C, Baeten D, Giral M, et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J Cell Biochem. 2008;103: 1681-1692.
46. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A. 2007;104:15448-15453.
47. Lozano JJ, Pallier A,Martinez-LlordellaM, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant. 2011;11:1916-1926.
48. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010; 120:1836-1847.
49. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.JClin Invest. 2010;120:1848-1861.
50. Baron D, Giral M, Brouard S. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve longterm kidney graft outcomes. Transpl Int. 2015;28:938-959.
51. Baron D, Ramstein G, Chesneau M, et al. A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int. 2015;87:984-995.
52. Lee JR,Muthukumar T, Dadhania D, et al. Urinary cellmRNA profiles predictive of human kidney allograft status. Immunol Rev. 2014;258: 218-240.
53. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013; 369:20-31.
54. Keslar KS, Lin M, Zmijewska AA, et al. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am J Transplant. 2013;13:1891-1897.
55. Amrouche L, Rabant M, Anglicheau D. MicroRNAs as biomarkers of graft outcome. Transplant Rev (Orlando). 2014;28:111-118.
56. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant. 2011;11:2221-2227.
57. Scian MJ, Maluf DG, David KG, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant. 2011;11:2110-2122.
58. Maluf DG, Dumur CI, Suh JL, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int. 2014;85: 439-449.
59. Hirt-Minkowski P, De Serres SA, Ho J. Developing renal allograft surveillance strategies-urinary biomarkers of cellular rejection. Can J Kidney Health Dis. 2015;2:28.
60. Johnston O, Cassidy H, O'Connell S, et al. Identification of 2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics Clin Appl. 2011;5:422-431.
61. Singh HK, Andreoni KA,Madden V, et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol. 2009; 20:416-427.
62. Singh HK, Reisner H, Derebail VK, et al. Polyomavirus nephropathy: quantitative urinary polyomavirus-Haufen testing accurately predicts the degree of intrarenal viral disease. Transplantation. 2015; 99:609-615.
63. Laskin BL, Singh HK, Beier UH, et al. The noninvasive urinary polyomavirus Haufen test predicts BK virus nephropathy in children after hematopoietic cell transplantation: a pilot study. [published online ahead of print February 18th, 2016]. Transplantation. 2016 doi: 10.1097/TP.0000000000001085.
64. Clerico A, Galli C, Fortunato A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med. 2012;50:1505-1517.
65. Devarajan P. Genomic and proteomic characterization of acute kidney injury. Nephron. 2015;131:85-91.
66. Kaufeld JK, GwinnerW, Scheffner I, et al. Urinary NGAL ratio is not a sensitive biomarker for monitoring acute tubular injury in kidney transplant patients: NGAL and ATI in renal transplant patients. J Transplant. 2012; 2012:563404.
67. Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem. 2014;51(Pt 3):335-351.
68. Rau S, Schonermarck U, Jager G, et al. BK virus-associated nephropathy: neutrophil gelatinase-associated lipocalin as a new diagnostic tool? Clin Transplant. 2013;27:E184-E191.
69. Goldstein SL, Chawla LS. Renal angina. Clin J AmSoc Nephrol. 2010;5: 943-949.
70. Menon S, Goldstein SL, Mottes T, et al. Urinary biomarker incorporation into the renal angina index early in intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort study. Nephrol Dial Transplant. 2016;31:586-594.
71. Mendes Mde F, Salgado JV, de Ribamar Lima J, et al. Increased urinary cystatinC level is associated with interstitial fibrosis and tubular atrophy in kidney allograft recipients. Clin Biochem. 2015;48:546-549.
72. CassidyH, Slyne J,O'Kelly P, et al.Urinary biomarkers of chronic allograft nephropathy. Proteomics Clin Appl. 2015;9:574-585.
73. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation. 2010;90:394-400.
74. Ho J,Wiebe C, Gibson IW, et al. Elevated urinary CCL2: Cr at 6months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Transplantation. 2014;98:39-46.
75. Rabant M, Amrouche L, Morin L, et al. Early low urinary CXCL9 and CXCL10 might predict immunological quiescence in clinically and histologically stable kidney recipients. Am J Transplant. 2015.
76. Hricik DE, Formica RN, Nickerson P, et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol. 2015;26:3114-3122.
77. GwinnerW,Metzger J, Husi H, et al. Proteomics for rejection diagnosis in renal transplant patients: where are we now? World J Transplant. 2016; 6:28-41.
78. Mao Y, Yu J, Chen J, et al. Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis. Transpl Immunol. 2008; 18:255-259.
79. Metzger J, Chatzikyrkou C, Broecker V, et al. Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl. 2011;5:322-333.
80. Wittke S, Haubitz M,Walden M, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant. 2005;5:2479-2488.
81. Akkina SK, Zhang Y, Nelsestuen GL, et al. Temporal stability of the urinary proteome after kidney transplant: more sensitive than protein composition? J Proteome Res. 2009;8:94-103.
82. Quintana LF, Campistol JM, Alcolea MP, et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction.Mol Cell Proteomics. 2009;8:1658-1673.
83. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol. 2009;20:428-435.
84. Sigdel TK, Salomonis N, Nicora CD, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteomics. 2014;13: 621-631.
85. Yang H, Mao Y, Yu J, et al. Diagnosis of c4d + renal allograft acute humoral rejection by urine protein fingerprint analysis. J Int Med Res. 2010;38:176-186.
86. Pisitkun T, Gandolfo MT, Das S, et al. Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation. Proteomics Clin Appl. 2012;6:268-278.
87. Jahnukainen T, Malehorn D, Sun M, et al. Proteomic analysis of urine in kidney transplant patients with BK virus nephropathy. J Am Soc Nephrol. 2006;17:3248-3256.
88. Gwinner W, Hinzmann K, Erdbruegger U, et al. Acute tubular injury in protocol biopsies of renal grafts: prevalence, associated factors and effect on long-term function. Am J Transplant. 2008;8:1684-1693.
89. Wang M, Jin Q, Tu H, et al. Detection of renal allograft dysfunction with characteristic protein fingerprint by serum proteomic analysis. Int Urol Nephrol. 2011;43:1009-1017.
90. Ho J, Lucy M, Krokhin O, et al. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. Am J Kidney Dis. 2009;53:584-595.
91. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010;78:1252-1262.
92. Bañón-Maneus E, Diekmann F, Carrascal M, et al. Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation. 2010; 89:548-558.
93. O'Riordan E, Orlova TN, Mendelev N, et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl. 2008;2:1025-1035.
94. Fernando M, Peake PW, Endre ZH. Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation. Biomark Med. 2014;8:1247-1262.
95. Wickman L, Afshinnia F, Wang SQ, et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol. 2013;24:2081-2095.
96. Sato Y, Wharram BL, Lee SK, et al. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009;20:1041-1052.
97. Craici IM, Wagner SJ, Bailey KR, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013;61:1289-1296.
98. O'Reilly VP, Wong L, Kennedy C, et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol. 2016.
99. Gupta R, Aggarwal A, Sinha S, et al. Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity. Lupus. 2016.
100. Vadasz Z, Goldeberg Y, Halasz K, et al. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clin Immunol. 2016;164:114-118.
101. Brunner HI, Bennett MR,Mina R, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012;64:2687-2697.
102. Fiorina P, Vezzulli P, Bassi R, et al. Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation. Diabetes Care. 2012;35:367-374.
103. Fiorina P, Perseghin G, De Cobelli F, et al. Altered kidney graft highenergy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care. 2007;30:597-603.
104. Lovinfosse P, Weekers L, Bonvoisin C, et al. Fluorodeoxyglucose F(18) positron emission tomography coupled with computed tomography in suspected acute renal allograft rejection. Am J Transplant. 2016;16: 310-316.
105. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001;344:947-954.
106. Muthukumar T, Ding R, Dadhania D, et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation. 2003;75:1565-1570.
107. Dadhania D, Muthukumar T, Ding R, et al. Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. Transplantation. 2003;75:1752-1754.
108. Ding R, Li B, Muthukumar T, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation. 2003;75: 1307-1312.
109. Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation. 2004;77:1866-1875.
110. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004;65:2390-2397.
111. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353: 2342-2351.
112. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short-and longterm graft function. Kidney Int. 2006;69:1683-1690.
113. Yannaraki M, Rebibou JM, Ducloux D, et al. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Transpl Int. 2006;19:759-768.
114. SeilerM, Brabcova I, Viklicky O, et al. Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation. Am J Transplant. 2007;7:423-433.
115. Renesto PG, Ponciano VC, Cenedeze MA, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant. 2007;7:1661-1665.
116. Manfro RC, Aquino-Dias EC, Joelsons G, et al. Noninvasive Tim-3 messenger RNA evaluation in renal transplant recipients with graft dysfunction. Transplantation. 2008;86:1869-1874.
117. Ozbay A, Torring C, Olsen R, et al. Transcriptional profiles in urine during acute rejection, bacteriuria, CMV infection and stable graft function after renal transplantation. Scand J Immunol. 2009;69:357-365.
118. Afaneh C, Muthukumar T, Lubetzky M, et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation. 2010;90:1381-1387.
119. van Ham SM, Heutinck KM, Jorritsma T, et al. Urinary granzyme A mRNA is a biomarker to diagnose subclinical and acute cellular rejection in kidney transplant recipients. Kidney Int. 2010;78:1033-1040.
120. Matignon M, Ding R, Dadhania DM, et al. Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction. J Am Soc Nephrol. 2014;25:1586-1597.
121. Hricik DE, Nickerson P, Formica RN, et al.Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13:2634-2644.
122. Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant. 2004;4:432-437.
123. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol. 2005;16:1849-1858.
124. Peng W, Chen J, Jiang Y, et al. Urinary fractalkine is a marker of acute rejection. Kidney Int. 2008;74:1454-1460.
125. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009;9: 1347-1353.
126. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation. 2009;87:1814-1820.
127. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11:2228-2234.
128. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation. 2011;92:878-882.
129. Hirt-Minkowski P,Amico P, Ho J, et al. Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant. 2012;12:1811-1823.
130. Blydt-Hansen TD, Gibson IW, Gao A, et al. Elevated urinary CXCL10-tocreatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation. Transplantation. 2015;99:797-804.
131. Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation. 1998;66:562-566.
132. Shoker A, George D, Yang H, et al. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. Transplantation. 2000;70:497-505.
133. Dugré FJ, Gaudreau S, Belles-Isles M, et al. Cytokine and cytotoxic molecule gene expression determined in peripheral blood mononuclear cells in the diagnosis of acute renal rejection. Transplantation. 2000;70:1074-1080.
134. Sabek O, Dorak MT, Kotb M, et al. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation. 2002;74: 701-707.
135. Netto MV, Fonseca BA, Dantas M, et al. Granzyme B, FAS-ligand and perforin expression during acute cellular rejection episodes after kidney transplantation: comparison between blood and renal aspirates. Transplant Proc. 2002;34:476-478.
136. Shin GT, Kim SJ, Lee TS, et al. Gene expression of perforin by peripheral blood lymphocytes as a marker of acute rejection. Nephron Clin Pract. 2005;100:c63-c70.
137. Veale JL, Liang LW, Zhang Q, et al. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. Hum Immunol. 2006;67:777-786.
138. Danger R, Paul C, Giral M, et al. Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection. PLoS One. 2013;8:e60702.